Universal Beteiligungs und Servicegesellschaft mbH Has $10.90 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Universal Beteiligungs und Servicegesellschaft mbH trimmed its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 119,545 shares of the medical equipment provider’s stock after selling 5,137 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Zimmer Biomet were worth $10,904,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Accent Capital Management LLC bought a new position in Zimmer Biomet in the 1st quarter worth approximately $35,000. Hilltop National Bank acquired a new stake in shares of Zimmer Biomet in the 2nd quarter valued at $42,000. True Wealth Design LLC raised its position in shares of Zimmer Biomet by 875.0% during the second quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 420 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of Zimmer Biomet during the first quarter valued at $48,000. Finally, Brooklyn Investment Group boosted its holdings in Zimmer Biomet by 45.9% in the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after acquiring an additional 145 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Wall Street Zen cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Sunday. Barclays lowered their price target on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research report on Wednesday, November 5th. Royal Bank Of Canada dropped their price target on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Finally, Johnson Rice set a $112.00 target price on shares of Zimmer Biomet in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $109.00.

Zimmer Biomet Stock Up 0.5%

Zimmer Biomet stock opened at $89.50 on Thursday. The firm has a market capitalization of $17.74 billion, a price-to-earnings ratio of 21.78, a PEG ratio of 2.29 and a beta of 0.67. The company’s 50 day simple moving average is $97.69 and its 200 day simple moving average is $96.79. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $85.33 and a fifty-two week high of $114.44.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter in the prior year, the company earned $1.74 EPS. The firm’s quarterly revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s payout ratio is presently 23.76%.

Insider Activity

In other news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.39% of the stock is owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.